A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 as an Adjunctive Treatment in patients with major depressive disorder (MDD).
Criteria:Be male or female outpatients, 18-65 years of age, inclusive.
Currently meet DSM-5 criteria for MDD without psychotic features, based on the SCID-5-CT, with a current major depressive episode (MDE).
Have inadequate response to 1 to 3 adequate antidepressant treatments in the current MDE.